Similarly, G9a was found to promote in vivo tumorigenicity in NSCLC, and downregulation of H3K9me2 in vitro decreased the expression of CSC markers such as CD133 and CD44 [53]. The gene discussed is EHMT2; the disease is non-small cell lung carcinoma.